Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoko Takebe

Showing results (41-50 of 140) with videos related to

Pageof 14
Sort By:
APL Bioengineering|November 3, 2025
Synergy between photonics and biological approaches-A review of combination therapies for cancer theranosticsJacob P Adams, Luke Pauli, Lin Wang, et al.
Academia Oncology|August 5, 2025
Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid modelsBeverly A Teicher, Naoko Takebe, Thomas S Dexheimer, et al.
Leukemia Research|February 28, 2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignanciesIvana Gojo, Michael L Tidwell, Jacqueline Greer, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2024
The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancersAllison Dunn, Naoko Takebe, Alice Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Principles and current strategies for targeting autophagy for cancer treatmentRavi K Amaravadi, Jennifer Lippincott-Schwartz, Xiao-Ming Yin, et al.
Molecular Cancer Therapeutics|March 11, 2024
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer DrugsUkhyun Jo, Yasuhiro Arakawa, Astrid Zimmermann, et al.
SLAS Discovery : Advancing Life Sciences R & D|April 10, 2025
Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroidsNathan P Coussens, Thomas S Dexheimer, Thomas Silvers, et al.
Cancer Science|November 9, 2017
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trialsAkihiro Hirakawa, Kan Yonemori, Fumie Kinoshita, et al.
Clinical Pharmacology and Therapeutics|March 31, 2019
A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer VaccinesAkihiro Hirakawa, Kazuki Sudo, Kan Yonemori, et al.
International Journal of Molecular Sciences|May 27, 2026
Real-Time Breath Diagnostics: Linking Molecular Pathways, Measurement Technologies, and Clinical TranslationVelmurugan Thavasi, Nirmal Choradia, Naoko Takebe, et al.
Pageof 14

Showing results (41-50 of 140) with videos related to

Sort By:
Pageof 14
APL Bioengineering|November 3, 2025
Synergy between photonics and biological approaches-A review of combination therapies for cancer theranosticsJacob P Adams, Luke Pauli, Lin Wang, et al.
Academia Oncology|August 5, 2025
Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid modelsBeverly A Teicher, Naoko Takebe, Thomas S Dexheimer, et al.
Leukemia Research|February 28, 2007
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignanciesIvana Gojo, Michael L Tidwell, Jacqueline Greer, et al.
Cancer Chemotherapy and Pharmacology|March 14, 2024
The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancersAllison Dunn, Naoko Takebe, Alice Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Principles and current strategies for targeting autophagy for cancer treatmentRavi K Amaravadi, Jennifer Lippincott-Schwartz, Xiao-Ming Yin, et al.
Molecular Cancer Therapeutics|March 11, 2024
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer DrugsUkhyun Jo, Yasuhiro Arakawa, Astrid Zimmermann, et al.
SLAS Discovery : Advancing Life Sciences R & D|April 10, 2025
Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroidsNathan P Coussens, Thomas S Dexheimer, Thomas Silvers, et al.
Cancer Science|November 9, 2017
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trialsAkihiro Hirakawa, Kan Yonemori, Fumie Kinoshita, et al.
Clinical Pharmacology and Therapeutics|March 31, 2019
A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer VaccinesAkihiro Hirakawa, Kazuki Sudo, Kan Yonemori, et al.
International Journal of Molecular Sciences|May 27, 2026
Real-Time Breath Diagnostics: Linking Molecular Pathways, Measurement Technologies, and Clinical TranslationVelmurugan Thavasi, Nirmal Choradia, Naoko Takebe, et al.
Pageof 14